Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome.
Identifieur interne : 002223 ( Ncbi/Merge ); précédent : 002222; suivant : 002224Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome.
Auteurs : L B Mitchell [Canada] ; D G Wyse ; H J DuffSource :
- Circulation [ 0009-7322 ] ; 1987.
English descriptors
- KwdEn :
- Adult, Atrioventricular Node (drug effects), Atrioventricular Node (physiopathology), Dose-Response Relationship, Drug, Electrocardiography, Female, Follow-Up Studies, Humans, Male, Middle Aged, Receptors, Adrenergic, beta (drug effects), Sotalol (blood), Sotalol (pharmacology), Sotalol (therapeutic use), Wolff-Parkinson-White Syndrome (drug therapy), Wolff-Parkinson-White Syndrome (physiopathology).
- MESH :
- chemical , blood : Sotalol.
- chemical , drug effects : Receptors, Adrenergic, beta.
- drug effects : Atrioventricular Node.
- drug therapy : Wolff-Parkinson-White Syndrome.
- chemical , pharmacology : Sotalol.
- physiopathology : Atrioventricular Node, Wolff-Parkinson-White Syndrome.
- chemical , therapeutic use : Sotalol.
- Adult, Dose-Response Relationship, Drug, Electrocardiography, Female, Follow-Up Studies, Humans, Male, Middle Aged.
Abstract
The beta-adrenoceptor-blocking and class III effects of sotalol were assessed in 11 patients with inducible orthodromic reciprocating tachycardia. Serum sotalol concentration, maximum exercise heart rate, and electrophysiologic study data were obtained at control, at the beta-adrenoceptor-blocking dosage (407 +/- 149 mg/day, 1.4 +/- 0.5 micrograms/ml), and at the maximum well-tolerated dosage (924 +/- 337 mg/day, 3.2 +/- 1.3 micrograms/ml). Class III effects (increases in anterograde and retrograde accessory connection effective refractory periods, ventricular effective refractory period, and the QT interval during fixed-rate atrial pacing) were evident at the beta-adrenoceptor-blocking dosage of sotalol and became more marked at the maximum well-tolerated dosage. For example, the mean anterograde accessory connection effective refractory period was significantly increased over control (272 +/- 41 msec) by the beta-adrenoceptor blocker (324 +/- 52 msec) and was further significantly increased by the maximum well-tolerated dose (364 +/- 37 msec). Similarly, the minimum preexcited RR interval during atrial fibrillation was increased in all patients at each dosage tested. Antiarrhythmic efficacy, defined by the absence of inducible, sustained, orthodromic reciprocating tachycardia and a minimum preexcited RR interval during atrial fibrillation of 300 msec or greater, was achieved in four patients at the beta-adrenoceptor-blocking dosage and in another four patients at the maximum well-tolerated dosage. These eight patients received long-term sotalol therapy and none has had recurrent, sustained reciprocating tachycardia during 15 +/- 12 months of follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)
PubMed: 2820614
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001C95
- to stream PubMed, to step Curation: 001C95
- to stream PubMed, to step Checkpoint: 001C95
Links to Exploration step
pubmed:2820614Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome.</title><author><name sortKey="Mitchell, L B" sort="Mitchell, L B" uniqKey="Mitchell L" first="L B" last="Mitchell">L B Mitchell</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Foothills General Hospital, Calgary, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Foothills General Hospital, Calgary, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Wyse, D G" sort="Wyse, D G" uniqKey="Wyse D" first="D G" last="Wyse">D G Wyse</name></author><author><name sortKey="Duff, H J" sort="Duff, H J" uniqKey="Duff H" first="H J" last="Duff">H J Duff</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1987">1987</date><idno type="RBID">pubmed:2820614</idno><idno type="pmid">2820614</idno><idno type="wicri:Area/PubMed/Corpus">001C95</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C95</idno><idno type="wicri:Area/PubMed/Curation">001C95</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C95</idno><idno type="wicri:Area/PubMed/Checkpoint">001C95</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001C95</idno><idno type="wicri:Area/Ncbi/Merge">002223</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome.</title><author><name sortKey="Mitchell, L B" sort="Mitchell, L B" uniqKey="Mitchell L" first="L B" last="Mitchell">L B Mitchell</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Foothills General Hospital, Calgary, Alberta, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, Foothills General Hospital, Calgary, Alberta</wicri:regionArea><wicri:noRegion>Alberta</wicri:noRegion></affiliation></author><author><name sortKey="Wyse, D G" sort="Wyse, D G" uniqKey="Wyse D" first="D G" last="Wyse">D G Wyse</name></author><author><name sortKey="Duff, H J" sort="Duff, H J" uniqKey="Duff H" first="H J" last="Duff">H J Duff</name></author></analytic><series><title level="j">Circulation</title><idno type="ISSN">0009-7322</idno><imprint><date when="1987" type="published">1987</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Atrioventricular Node (drug effects)</term><term>Atrioventricular Node (physiopathology)</term><term>Dose-Response Relationship, Drug</term><term>Electrocardiography</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Receptors, Adrenergic, beta (drug effects)</term><term>Sotalol (blood)</term><term>Sotalol (pharmacology)</term><term>Sotalol (therapeutic use)</term><term>Wolff-Parkinson-White Syndrome (drug therapy)</term><term>Wolff-Parkinson-White Syndrome (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Sotalol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Adrenergic, beta</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Atrioventricular Node</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Wolff-Parkinson-White Syndrome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Sotalol</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Atrioventricular Node</term><term>Wolff-Parkinson-White Syndrome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Sotalol</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Dose-Response Relationship, Drug</term><term>Electrocardiography</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The beta-adrenoceptor-blocking and class III effects of sotalol were assessed in 11 patients with inducible orthodromic reciprocating tachycardia. Serum sotalol concentration, maximum exercise heart rate, and electrophysiologic study data were obtained at control, at the beta-adrenoceptor-blocking dosage (407 +/- 149 mg/day, 1.4 +/- 0.5 micrograms/ml), and at the maximum well-tolerated dosage (924 +/- 337 mg/day, 3.2 +/- 1.3 micrograms/ml). Class III effects (increases in anterograde and retrograde accessory connection effective refractory periods, ventricular effective refractory period, and the QT interval during fixed-rate atrial pacing) were evident at the beta-adrenoceptor-blocking dosage of sotalol and became more marked at the maximum well-tolerated dosage. For example, the mean anterograde accessory connection effective refractory period was significantly increased over control (272 +/- 41 msec) by the beta-adrenoceptor blocker (324 +/- 52 msec) and was further significantly increased by the maximum well-tolerated dose (364 +/- 37 msec). Similarly, the minimum preexcited RR interval during atrial fibrillation was increased in all patients at each dosage tested. Antiarrhythmic efficacy, defined by the absence of inducible, sustained, orthodromic reciprocating tachycardia and a minimum preexcited RR interval during atrial fibrillation of 300 msec or greater, was achieved in four patients at the beta-adrenoceptor-blocking dosage and in another four patients at the maximum well-tolerated dosage. These eight patients received long-term sotalol therapy and none has had recurrent, sustained reciprocating tachycardia during 15 +/- 12 months of follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2820614</PMID><DateCreated><Year>1987</Year><Month>11</Month><Day>19</Day></DateCreated><DateCompleted><Year>1987</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0009-7322</ISSN><JournalIssue CitedMedium="Print"><Volume>76</Volume><Issue>4</Issue><PubDate><Year>1987</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Circulation</Title><ISOAbbreviation>Circulation</ISOAbbreviation></Journal><ArticleTitle>Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome.</ArticleTitle><Pagination><MedlinePgn>810-8</MedlinePgn></Pagination><Abstract><AbstractText>The beta-adrenoceptor-blocking and class III effects of sotalol were assessed in 11 patients with inducible orthodromic reciprocating tachycardia. Serum sotalol concentration, maximum exercise heart rate, and electrophysiologic study data were obtained at control, at the beta-adrenoceptor-blocking dosage (407 +/- 149 mg/day, 1.4 +/- 0.5 micrograms/ml), and at the maximum well-tolerated dosage (924 +/- 337 mg/day, 3.2 +/- 1.3 micrograms/ml). Class III effects (increases in anterograde and retrograde accessory connection effective refractory periods, ventricular effective refractory period, and the QT interval during fixed-rate atrial pacing) were evident at the beta-adrenoceptor-blocking dosage of sotalol and became more marked at the maximum well-tolerated dosage. For example, the mean anterograde accessory connection effective refractory period was significantly increased over control (272 +/- 41 msec) by the beta-adrenoceptor blocker (324 +/- 52 msec) and was further significantly increased by the maximum well-tolerated dose (364 +/- 37 msec). Similarly, the minimum preexcited RR interval during atrial fibrillation was increased in all patients at each dosage tested. Antiarrhythmic efficacy, defined by the absence of inducible, sustained, orthodromic reciprocating tachycardia and a minimum preexcited RR interval during atrial fibrillation of 300 msec or greater, was achieved in four patients at the beta-adrenoceptor-blocking dosage and in another four patients at the maximum well-tolerated dosage. These eight patients received long-term sotalol therapy and none has had recurrent, sustained reciprocating tachycardia during 15 +/- 12 months of follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>L B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department of Medicine, Foothills General Hospital, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyse</LastName><ForeName>D G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>H J</ForeName><Initials>HJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circulation</MedlineTA><NlmUniqueID>0147763</NlmUniqueID><ISSNLinking>0009-7322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011943">Receptors, Adrenergic, beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>A6D97U294I</RegistryNumber><NameOfSubstance UI="D013015">Sotalol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001283" MajorTopicYN="N">Atrioventricular Node</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011943" MajorTopicYN="N">Receptors, Adrenergic, beta</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013015" MajorTopicYN="N">Sotalol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014927" MajorTopicYN="N">Wolff-Parkinson-White Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2820614</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Duff, H J" sort="Duff, H J" uniqKey="Duff H" first="H J" last="Duff">H J Duff</name><name sortKey="Wyse, D G" sort="Wyse, D G" uniqKey="Wyse D" first="D G" last="Wyse">D G Wyse</name></noCountry><country name="Canada"><noRegion><name sortKey="Mitchell, L B" sort="Mitchell, L B" uniqKey="Mitchell L" first="L B" last="Mitchell">L B Mitchell</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002223 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002223 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:2820614
|texte= Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:2820614" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |